Nordic Group And Nippon Kayaku

PARIS, December 22, 2010 - Nippon Kayaku (NK) and the Nordic Pharma Group (Nordic) have signed a licensing agreement under which NK grants exclusive rights to NORDIC for the development and commercialisation of Spanidin(R) (gusperimus) in selected territories outside of Japan, including Europe.